SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+6.25%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$239M
AUM Growth
+$239M
(+33%)
Cap. Flow
+$52.6M
Cap. Flow
% of AUM
22.02%
Top 10 Holdings %
Top 10 Hldgs %
71.73%
Holding
24
New
4
Increased
14
Reduced
2
Closed
4
Top Buys
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$16.2M |
| 2 |
AnaptysBio
ANAB
|
$10.4M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$9.21M |
| 4 |
Sarepta Therapeutics
SRPT
|
$7.81M |
| 5 |
Cogent Biosciences
COGT
|
$6.16M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$20.2M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$9.78M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$3.32M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$944K |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$358K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Crinetics Pharmaceuticals
CRNX
$2.92B
| $33.5M | 14.02% | 1,126,579 +187,902 | +20% | +$5.59M |
|
2
KalVista Pharmaceuticals
KALV
$678M
| $17.4M | 7.3% | 1,810,246 +397,910 | +28% | +$3.83M |
|
|
3
Cogent Biosciences
COGT
$1.69B
| $17.3M | 7.25% | 1,775,415 +632,047 | +55% | +$6.16M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $16.8M | 7.02% | 1,124,459 -63,342 | -5% | -$944K |
|
5
Biogen
BIIB
$19.4B
| $16.6M | 6.96% | 64,676 +23,629 | +58% | +$6.07M |
|
|
6
Amylyx Pharmaceuticals
AMLX
$836M
| $16.2M | 6.79% | +886,143 | New | +$16.2M |
|
7
Cytokinetics
CYTK
$4.23B
| $14.6M | 6.11% | 495,168 +88,943 | +22% | +$2.62M |
|
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $14.4M | 6.01% | 118,401 +64,406 | +119% | +$7.81M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $12.8M | 5.38% | 111,045 +11,550 | +12% | +$1.34M |
|
|
10
Syndax Pharmaceuticals
SNDX
$1.41B
| $11.7M | 4.91% | 807,969 +634,252 | +365% | +$9.21M |
|
11
iTeos Therapeutics
ITOS
$449M
| $10.9M | 4.56% | 994,756 +358,598 | +56% | +$3.93M |
|
12
Ascendis Pharma
ASND
$11.8B
| $10.5M | 4.41% | 112,473 +34,031 | +43% | +$3.19M |
|
|
13
AnaptysBio
ANAB
$569M
| $10.4M | 4.34% | +577,101 | New | +$10.4M |
|
14
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.7M | 4.06% | 109,685 +17,059 | +18% | +$1.51M |
|
15
Astria Therapeutics
ATXS
$349M
| $9.09M | 3.81% | 1,219,093 +581,236 | +91% | +$4.34M |
|
16
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.96M | 2.91% | 982,458 +27,602 | +3% | +$195K |
|
17
argenx
ARGX
$43.6B
| $4.95M | 2.07% | 10,074 +5,993 | +147% | +$2.95M |
|
|
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.13M | 1.31% | 136,743 -15,617 | -10% | -$358K |
|
19
Jasper Therapeutics
JSPR
$45.5M
| $971K | 0.41% | +1,387,015 | New | +$971K |
|
20
Merus
MRUS
$4.98B
| $945K | 0.4% | +40,066 | New | +$945K |
|
|
21
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | -107,406 | Closed | -$9.78M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| – | – | -70,559 | Closed | -$3.32M |
|
23
Scilex Holding
SCLX
$124M
| – | – | -10,390 | Closed | -$57.9K |
|
|
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – | -524,811 | Closed | -$20.2M |
|